Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Company Directory
Abiomed
22 Cherry Hill Drive
Danvers
MA 01923
USA
[t] 001 978 777 5410
[f] 001 978 777 5411
Abiomed is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery.

The company's products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart.
Abiomed enrolls first patient in percutaneous heart pump study
02 April, 2013
Abiomed enrolls the first patient in RECOVER RIGHT, an Investigational Device Exemption (IDE) study of Impella RP (Right Peripheral).
FDA 515i panel recommends Class III status for Abiomed's temporary ventricular support devices
10 December, 2012
The US Food and Drug Administration's (FDA) Circulatory System Devices Panel votes to retain Class III status for the temporary ventricular support devices within the non-roller type cardiopulmonary bypass blood pumps category, which includes Abiomed's Impella.
Abiomed receives FDA 510(k) clearance for percutaneous heart pump
11 September, 2012
Abiomed receives 510(k) clearance from the US Food and Drug Administration (FDA) for a new percutaneous, catheter-based Impella device providing peak flows of approximately four litres of blood per minute.
Heart pump provides percutaneous haemodynamic support
18 June, 2012
Abiomed receives Health Canada approval to market the Impella cVAD device, a new percutaneous Impella heart pump that provides peak flow of approximately four litres of blood per minute.
Abiomed's Impella cVAD device receives CE Mark
13 April, 2012
Abiomed receives CE Marking approval in the European Union to market the Impella cVAD device, a new percutaneous Impella heart pump that provides peak flow of approximately four litres of blood per minute.
Abiomed reports first patient supported with Impella cVAD
05 April, 2012
Abiomed is reporting the successful first human use of the Impella cVAD device, a new, percutaneous Impella heart pump that provides peak flow of approximately four litres of blood per minute.
Abiomed focuses on expanding its heart recovery strategy
12 December, 2011
Abiomed is expanding the company's heart recovery strategy along with new initiatives that are expected to enhance strong, multi-year double digit sales and earnings growth.
Study shows large infarcts in stable STEMI patient populations
20 September, 2011
Abiomed enrolls its first patient in the MINI-AMI, an FDA prospective, randomized, controlled multi-centre study to assess the role of 24-hours of direct unloading of the left ventricle with Impella 2.5 support to reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) without cardiogenic shock.
Abiomed plans multi-site trial to assess if Impella 2.5 can shrink infarct size
06 December, 2010
Abiomed receives conditional approval from the US Food and Drug Administration to begin MINI-AMI, a prospective, randomized, controlled multi-site trial to assess the potential role of the Impella 2.5 in reducing infarct size in patients with ST-elevation myocardial infarction (STEMI).
Abiomed offers advanced training programme for haemodynamic support
04 October, 2010
Abiomed is launching a specialised partner programme that enables select top healthcare institutions to provide advanced training in haemodynamic support and complex patient management to better facilitate heart muscle recovery.
Percutaneous catheter-based axial flow pump solution supports first patient
13 September, 2010
Abiomed reports that the first patient was successfully supported for six days by the Impella Right Peripheral (RP) at the Providence Heart + Lung Institute at St Paul’s Hospital in Vancouver, British Columbia.
Abiomed partners Opsens to integrate fibre optic sensors in catheters
28 January, 2010
Abiomed forms a strategic partnership with Opsens, a leading developer of fibre optic sensors which will see Opsens' breakthrough sensor technology being integrated into the Impella catheter to provide robust blood pressure measurements that can be used to enhance Impella's performance and ease-of-use.
Abiomed circulatory assist device is evaluated for safety in PCI procedures
21 December, 2009
Results from the Europella registry, evaluating the safety and feasibility of the Abiomed Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures is now published the Journal of the American College of Cardiology (JACC).
Improved cardiac output for Impella 2.5 trial patients
25 September, 2009
Abiomed has reported on the results of clinical trials involving the Impella 2.5 arm of the MACH II trial
USpella results for 181 patients
23 September, 2009
Results announced from multi-centre clinical evaluation of left ventricular support using Impella 2.5
Timetable of Abiomed events at TCT in San Francisco
09 September, 2009
Investor and analyst meeting kicks off series of symposia and presentations from Abiomed being held at the Transcatheter Cardiovascular Therapeutics meeting in San Francisco held during the week of September 21st
Total replacement heart patient dies
03 September, 2009
The first patient to receive a total replacement heart from AbioCor has died of post-operative conditions two and a half months after receiving the device
Portable circulatory support driver receives CE Mark
03 April, 2008
Abiomed has received CE Mark approval for its Portable Circulatory Support Driver which enables the device to be sold in all European Union countries as well as many other countries worldwide that accept this approval for registration.
Abiomed updates FDA status of its Impella 2.5 circulatory support device
28 March, 2008
Abiomed has issued an update on the 510(k) clearance process related to its Impella 2.5 circulatory support device.
Portable Circulatory Support Driver receives CE Mark approval
28 March, 2008
Abiomed has received the CE Mark for its Portable Circulatory Support Driver and will now be able to sell the device in all European Union countries as well as many other countries worldwide that accept this approval for registration.
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo